| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/18/2009 | CA2479216C Dipyridodiazepinones as reverse transcriptase inhibitors |
| 08/18/2009 | CA2440710C Medicine of post-traumatic stress disorder |
| 08/18/2009 | CA2429270C Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 08/18/2009 | CA2429133C Novel imidazole derivatives, production method thereof and use thereof |
| 08/18/2009 | CA2412208C Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 08/18/2009 | CA2409379C Use of riluzole or its salts for preventing and treating adrenoleukodystrophy |
| 08/18/2009 | CA2401569C Low dose entecavir formulation and use |
| 08/18/2009 | CA2400268C Pyrrolopyrimidinone derivatives, process of preparation and use |
| 08/18/2009 | CA2393568C Diarylmethylpiperazines |
| 08/18/2009 | CA2392030C Urea compounds having muscarinic receptor antagonist activity |
| 08/18/2009 | CA2392028C Carbamate derivatives having muscarinic receptor antagonist activity |
| 08/18/2009 | CA2387394C Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
| 08/18/2009 | CA2377254C Non-malignant disease treatment with ras antagonists |
| 08/18/2009 | CA2362760C Camptothecin derivatives having antitumor activity |
| 08/18/2009 | CA2353835C Composition set and kit for use in intraocular surgery |
| 08/18/2009 | CA2335250C Temperature-sensitive liposomal formulation |
| 08/18/2009 | CA2333004C Formoterol polymorphs |
| 08/18/2009 | CA2315141C Pharmaceutical compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof |
| 08/18/2009 | CA2288215C Use of immunomodulating agents |
| 08/18/2009 | CA2276764C Acridine derivatives as opioid analgesics |
| 08/18/2009 | CA2230240C Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 08/18/2009 | CA2226425C Drug delivery compositions for improved stability of steroids |
| 08/18/2009 | CA2224150C Use of locally applied dna fragments |
| 08/18/2009 | CA2224008C The treatment of hiv and other viral infections using combinatorial therapy |
| 08/18/2009 | CA2184841C Recombinant adenovirus coding for glial-derived neurotrophic factor (gdnf) |
| 08/18/2009 | CA2174526C Pseudodipeptide product possessing an imidazole group and the therapeutic, cosmetological and agri-food applications of the said product |
| 08/18/2009 | CA2124059C Octacyclodepsipeptides having an endoparasiticidal action |
| 08/17/2009 | CA2709732A1 Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis |
| 08/14/2009 | CA2654210A1 Association of a sinus current inhibitor if and a beta blocker |
| 08/13/2009 | WO2009100456A2 Inhibition and treatment of gastrointestinal biofilms |
| 08/13/2009 | WO2009100438A2 Compounds that enhance atoh-1 expression |
| 08/13/2009 | WO2009100435A2 Sclerotherapy for varicose veins |
| 08/13/2009 | WO2009100431A1 Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings |
| 08/13/2009 | WO2009100422A2 Drug delivery system comprising microparticles and gelation system |
| 08/13/2009 | WO2009100406A2 Topical formulations for the treatment of psoriasis |
| 08/13/2009 | WO2009100380A1 Use of ranolazine for treating pain |
| 08/13/2009 | WO2009100375A1 Substituted imidazopyridazines useful as kinase inhibitors |
| 08/13/2009 | WO2009100370A1 Methods of treating migraine based on rhythmic sodium levels |
| 08/13/2009 | WO2009100367A2 Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome |
| 08/13/2009 | WO2009100349A1 Analogues of (-)-picropodophyllin, synthesis and uses thereof |
| 08/13/2009 | WO2009100335A1 Phosphate derivatives of substituted benzoxazoles |
| 08/13/2009 | WO2009100333A2 Sweetener compositions and methods of making them |
| 08/13/2009 | WO2009100326A1 Abca-1 elevating compounds and the use thereof |
| 08/13/2009 | WO2009100323A2 Methods of using carboxylic amides as antimicrobial agents |
| 08/13/2009 | WO2009100305A1 Pteridine derivatives for treating respiratory disease |
| 08/13/2009 | WO2009100282A1 Furo-and thieno[3,2-c] pyridines |
| 08/13/2009 | WO2009100278A2 Beverage comprising arginine |
| 08/13/2009 | WO2009100275A2 Compositions and devices |
| 08/13/2009 | WO2009100272A2 Effervescent compositions |
| 08/13/2009 | WO2009100258A1 Pharmaceutical solid state forms |
| 08/13/2009 | WO2009100250A1 Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| 08/13/2009 | WO2009100218A2 Kruppel-like transcription factor klf4/gklf and uses thereof |
| 08/13/2009 | WO2009100181A2 Absorbent ingestible agents and associated methods of manufacture and use |
| 08/13/2009 | WO2009100171A1 Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| 08/13/2009 | WO2009100170A1 Dual pharmacophores - pde4-muscarinic antagonistics |
| 08/13/2009 | WO2009100166A1 Dual pharmacophores-pde4-muscarinic antagonistics |
| 08/13/2009 | WO2009100121A1 Gamma-glutamyl transpeptidase inhibitors and methods of use |
| 08/13/2009 | WO2009100118A1 Extended release hydrocodone acetaminophen and related methods and uses thereof |
| 08/13/2009 | WO2009100116A1 Oligodendrocyte precursor cell composition and methods of use |
| 08/13/2009 | WO2009100107A2 Alendronate formulations, method of making and method of use thereof |
| 08/13/2009 | WO2009100095A1 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity |
| 08/13/2009 | WO2009100090A1 Prodrugs of cgrp receptor antagonist |
| 08/13/2009 | WO2009100057A1 Substituted cyclopentanes having prostaglandin activity |
| 08/13/2009 | WO2009100037A1 Methods for treating a condition characterized by dysfunction in protein homeostasis |
| 08/13/2009 | WO2009100014A1 System for fluorinating organic compounds |
| 08/13/2009 | WO2009100011A2 Targeted cellular selectivity of surface active molecules |
| 08/13/2009 | WO2009099999A2 Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage |
| 08/13/2009 | WO2009099998A2 Therapeutic treatment for lung conditions |
| 08/13/2009 | WO2009099982A1 2-aminopyridine kinase inhibitors |
| 08/13/2009 | WO2009099942A2 Chemically modified oligonucleotides and uses thereof |
| 08/13/2009 | WO2009099890A2 Methods of treating skin with aromatic skin-active ingredients |
| 08/13/2009 | WO2009099886A1 Methods of improving dha deposition and related function and/or development |
| 08/13/2009 | WO2009099820A2 Modulating body weight |
| 08/13/2009 | WO2009099801A1 Pyrido [4, 3-d] pyrimidinone derivatives as kinase inhibitors |
| 08/13/2009 | WO2009099741A1 Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| 08/13/2009 | WO2009099734A1 Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| 08/13/2009 | WO2009099716A1 Novel vaccines against multiple subtypes of dengue virus |
| 08/13/2009 | WO2009099676A1 Type 5 adenylyl cyclase inhibitors for providing cardiac protection |
| 08/13/2009 | WO2009099673A1 Ruthenium compounds and compositions |
| 08/13/2009 | WO2009099672A2 Breaking immunological tolerance with a genetically encoded unnatural amino acid |
| 08/13/2009 | WO2009099651A1 Use of picoplatin and cetuximab to treat colorectal cancer |
| 08/13/2009 | WO2009099650A2 Treatment of bladder diseases with a tlr7 activator |
| 08/13/2009 | WO2009099636A1 Conjugation of small molecules to octaarginine transporters for overcoming multi-drug resistance |
| 08/13/2009 | WO2009099634A2 Picoplatin and amrubicin to treat lung cancer |
| 08/13/2009 | WO2009099620A1 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
| 08/13/2009 | WO2009099596A2 Macrocyclic serine protease inhibitors |
| 08/13/2009 | WO2009099594A1 Certain chemical entities, compositions and methods |
| 08/13/2009 | WO2009099586A2 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
| 08/13/2009 | WO2009099582A2 Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide |
| 08/13/2009 | WO2009099567A2 Crosslinked polysaccharides and methods of production thereof |
| 08/13/2009 | WO2009099563A2 Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease |
| 08/13/2009 | WO2009099553A2 Use of kinase inhibitor in treatment of atherosclerosis |
| 08/13/2009 | WO2009099489A2 Compositions and methods for improving cardiovascular health |
| 08/13/2009 | WO2009099455A1 Oral care product and methods of use and manufacture thereof |
| 08/13/2009 | WO2009099454A1 Oral care product and methods of use and manufacture thereof |
| 08/13/2009 | WO2009099453A1 Oral care product and methods of use and manufacture thereof |
| 08/13/2009 | WO2009099452A1 Oral care product and methods of use and manufacture thereof |
| 08/13/2009 | WO2009099451A1 Arginine salts and their uses for the treatment of illnesses in the oral cavity |
| 08/13/2009 | WO2009099450A1 Oral care regimen |
| 08/13/2009 | WO2009099392A1 Compositions of phytosterols with enhanced bioavailability |